A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma

PURPOSE: Consolidation/maintenance therapy induces deep remission in patients with multiple myeloma (MM); however, the most suitable regimen has been under investigation. The combination therapy with bortezomib, lenalidomide and dexamethasone (VRD) is a powerful regimen for relapsed/refractory as we...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibata, Soushi, Sato, Tsutomu, Kuroda, Hiroyuki, Nagamachi, Yasuhiro, Iyama, Satoshi, Fujimi, Akihito, Kamihara, Yusuke, Konuma, Yuichi, Yoshida, Masahiro, Tatekoshi, Ayumi, Hashimoto, Akari, Horiguchi, Hiroto, Ono, Kaoru, Murase, Kazuyuki, Takada, Kohichi, Miyanishi, Koji, Kobune, Masayoshi, Hirayama, Yasuo, Kato, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083756/
https://www.ncbi.nlm.nih.gov/pubmed/27738809
http://dx.doi.org/10.1007/s00280-016-3163-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083756/
https://www.ncbi.nlm.nih.gov/pubmed/27738809
http://dx.doi.org/10.1007/s00280-016-3163-y

Ejemplares similares